A Phase II Study of Tislelizumab Immunotherapy in People with Recurrent or Persistent Classical Hodgkin Lymphoma


Full Title

A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma


The purpose of this study is to assess the safety and effectiveness of the investigational immunotherapy tislelizumab in patients with classical Hodgkin lymphoma that has come back or continued to grow despite prior treatment. Tislelizumab blocks a protein called PD-1 that usually acts as a “brake” on the immune system. Blocking this protein is like releasing the brakes, enabling the immune system to detect and destroy cancer cells. Tislelizumab is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have recurrent or persistent classical Hodgkin lymphoma.
  • At least 4 weeks must pass between the completion of prior treatment and receipt of tislelizumab. Prior immunotherapy is not permitted.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alison Moskowitz at 646-608-3726.





Disease Status

Relapsed or Refractory